| Literature DB >> 24225380 |
Abstract
Particle size dictates where aerosolized pathogens deposit in the respiratory tract, thereafter the pathogens potential to cause disease is influenced by tissue tropism, clearance kinetics and the host immunological response. This interplay brings pathogens into contact with a range of tissues spanning the respiratory tract and associated anatomical structures. In animal models, differential deposition within the respiratory tract influences infection kinetics for numerous select agents. Greater numbers of pathogens are required to infect the upper (URT) compared with the lower respiratory tract (LRT), and in comparison the URT infections are protracted with reduced mortality. Pathogenesis in the URT is characterized by infection of the URT lymphoid tissues, cervical lymphadenopathy and septicemia, closely resembling reported human infections of the URT. The olfactory, gastrointestinal, and ophthalmic systems are also infected in a pathogen-dependent manner. The relevant literature is reviewed with respect to particle size and infection of the URT in animal models and humans.Entities:
Keywords: aerosols; infection; particle size; pneumonia; upper respiratory tract
Mesh:
Substances:
Year: 2013 PMID: 24225380 PMCID: PMC3925716 DOI: 10.4161/viru.27172
Source DB: PubMed Journal: Virulence ISSN: 2150-5594 Impact factor: 5.882
Table 1. Sources of bioaerosol
| Healthcare | Surgical or dental procedures | Up to 50 µme | |
| Hospital air | <2 µm (22%), 2 to 6 µm (30%), >5 µm (48%) | ||
| Mechanical ventilators, bed making, and resuspension on dust or skin squamae | 0.3 to >5 µm | ||
| Water industry | Cooling towers | <5 up to >100 µm (bimodal peaks at <5 µm and 20–40 µm) | |
| Wastewater irrigation sites | 1.0 to 5.9 µm | ||
| Agricultural/forestry industries | Grain harvesting, food processing, dust, and/or feces from animal housing and farming activities | 0.9 to 18.9 µm | |
| Insecticidal crop spraying | 4.6 to 39 µmd | ||
| 12.3 to 37.1 µmc | |||
| 15 to 45 µmc | |||
| 60 to 100 µm (kromecote card); 5.3 to 7.3 µm (Anderson cascade impactor) | |||
| Genetic dispersion | Pollen grains: 10 to 100 µme | ||
| Fungal spores: 1 to 50 µme | |||
| Postal and shopping industry | Mail sorting and opening | 0.3 to >5 µm; 19.6-fold increase in particles >5 µm | |
| Mist machine | “between 40 and 70 µm” | ||
| Leisure activities | Marine activities, e.g., surfing | 24 to 44 µm, median 34 µm | |
| Whirlpools | <1 to 15 µm dependent on turbulence | ||
| Human activity | Breathing | <0.8 to 2 µm | |
| Speaking | 16 to 125 µm | ||
| <0.8 to 7 µm | |||
| Shouting | 0.5 to 10 µm (mean = 1.0 µm) | ||
| Coughing | 0.62 to 15.9 µm | ||
| 40 to 125 µm | |||
| Sneezing | 7 to 125 µm | ||
| Vuvuzela playing | 0.5 to >10 µm (mean = 1.3 µm) | ||
| Showering | Hot water (5.2 to 7.5 µm) | ||
| Cold water (2.5 to 3.1 µm) | |||
| Miscellaneous | Pulp waste water treatment plant | 2.4 to 3.5 µm (median); 99.9% of particles were below 15 µm | |
| Building tower (sweeping dust containing pigeon feces) | 1.1 to 11.0 µm |
a Aerodynamic diameter; bdistributions should be viewed with caution as often experiments used samplers with cut off limits less than 15 µm and therefore were preferentially selective for particles smaller than this size; cspray-dried Bacillus thuringiensis produced at different homogenization speeds; dnon-biological aerosols for vector control; eprocedure- or species-dependent.
Table 2. Tissues that may represent the primary site of deposition, clearance and infection during exposure to a bioaerosol
| Anatomical region | Tissue(s) | Function | Epithelium |
|---|---|---|---|
| Nasopharyngeal/Oropharyngeal | Nares to nasopharynx | Inhalation, filtration, and mucociliary clearance of foreign particles; warming/humidification of air | Ciliated |
| Paranasal sinuses | Humidification of air; mucociliary clearance of foreign particles | Ciliated | |
| Olfactory epithelium | Detection of odors | Sensory | |
| Mouth to oropharynx | Mastication and ingestion; inhalation | Non-ciliated | |
| Tonsils, adenoidsa | Defense against inhaled/ingested pathogens; URT mucosal immunity | Lymphoepithelial | |
| Tracheobronchial | Larynx | Sound generation; mucociliary clearance | Ciliated/non-cilated |
| Trachea | Air conduction; mucociliary clearance | Ciliated | |
| Bronchi to bronchioles | Air conduction and particulate filtration; mucociliary clearance | Ciliated | |
| Pulmonary | Respiratory bronchioles to alveoli | Air conduction; gaseous exchange; pulmonary clearance and immunity | Non-ciliated |
| Ocular | Ocular conjunctiva | Lubrication of ocular region | Non-ciliated |
| Nasolacrimal duct | Drainage of excess tear fluid | Non-ciliated | |
| Gastrointestinal | Esophageal, stomach and intestinal epithelium | Digestion and absorption of ingested material, including inhaled particles trapped in the mucociliary escalator | Non-ciliated |
| Peyer patches | Defense against ingested pathogens | Lymphoepithelial |
a Nasal-associated lymphoid tissue (NALT) represents the rodent equivalent.

Figure 1. Schematic of the interplay between deposition sites and clearance mechanisms in the respiratory tract. BALT, bronchial-associated lymphoid tissue; LALT, lung-associated lymphoid tissue; LNs, lymph nodes; NALT, nasal-associated lymphoid tissue.
Table 3. Influence of aerosol particle size on the respiratory lethal dose values for respiratory pathogens
| Particle size (μm) | VEEV (pfu) | EEEVa (pfu) | Ricinb (μg kg−1) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Animal species | Guinea pig | Mouse (A/Jola) | Guinea pig | Mouse (Balb/c) | Guinea pig | Rhesus macaque | Guinea pig | Mouse (Balb/c) | Guinea pig | Guinea pig | Guinea pig | Mouse (Balb/c) | Mouse (Balb/c) |
| 1.0–3.0 | 0.23–3.4 × 105 | 2.43 × 103 | 0.3–1.0 × 105 | 6.01 × 102 | 2.5 | 14–17.3 | ANNEX A 1.3–1.9 × 102 | 4.0–5.0 | 1.9 × 106 | 20 | 0.52–1.1 × 104 | 4.6–6.2 × 102 | 12.2 |
| 4.0–6.5 | 2.21 × 105 | ND | ND | ND | 6.5 × 103 | 2.4 × 102 | ND | ND | 5.27 × 107 | 1.9 × 104 | ND | ND | ND |
| 8.5–13.0 | 0.7–5.7 × 106 | 7.65 × 103 | 0.7–2.1 × 105 | 2.95 × 103 | 1.95 × 104 | 5.5–8.72 × 102 | ANNEX B 0.88–1.6 × 106 | 12.0 | > 2.4 × 109 | 2.8 × 105 | 3.0 × 104 | 2.9 × 105 | No lethality |
| 20.0–25.0 | ND | ND | ND | ND | ND | 3.75–4.45 × 103 | ND | ND | ND | ND | ND | ND | ND |
| Method 1–3 μm | COLL | COLL | COLL | COLL | NK | Atomizer | COLL | NK | NK | NK | COLL | COLL | COLL |
| Method >4 μm | STAG | FFAG | STAG | FFAG | NK | STAG | STAG | NK | NK | NK | STAG | STAG | STAG |
| References | |||||||||||||
cfu, colony forming unit; COLL, Collison nebulizer; EEEV, eastern equine encephalitis virus; FFAG, flow-focusing aerosol generator; ND, not determined; NK, not known; pfu, plaque forming unit; STAG, spinning top aerosol generator; VEEV, Venezuelan Equine Encephalitis virus. a, values represent LD50 values from two virus strains (ArgM and NJ1959); b, no lethality using 45 µg kg−1
Table 4. Effect of aerosol particle size and deposition site on infection kinetics and pathology for selected pathogens in animal models of infection
| Pathogen | ||||||||
|---|---|---|---|---|---|---|---|---|
| Particle size | 1 | 12 | 1 | 12 | 1 | 12 | 1 | 12 |
| Deposition site | Lungs | Nasal mucosa | Lungs | Nasal mucosa | Lungs | Nasal mucosa | Lungs | Nasal mucosa |
| MLD (cfu) | 6.01 × 102 | 2.95 × 103 | 2.43 × 103 | 7.65 × 103 | 4 | 12 | 17 | 8.72 × 102 |
| MTTD (h) | 72 ± 0 | 90 ± 11.5 | 101.6 ± 10.4 | 161.0 ± 16.1 | 73.8 ± 11.3 | 174.7 ± 14.9 | 138.9 ± 8.8 | 224.5 ± 9.6 |
| Mortalitya (%) | 100 | 80 | 78 | 56 | 100 | 90 | 100 | 83 |
| Pathogenesis | 1° pneumonia | Nasal ulceration | BALT infection | Nasal ulceration | 1° pneumonia | Nasal ulceration | 1° pneumonia | Nasal ulceration |
| Splenitis | NALT infection | Mediastinal LN | NALT infection | Splenitis | NALT infection | Splenitis | Tonsillitis | |
| Septicemia | Cervical adenitis | Splenitis | Cervical adenitis | Septicemia | Cervical adenitis | Septicemia | Cervical adenitis | |
| Splenitis | Septicemia | Splenitis | Splenitis | Splenitis | ||||
| Septicemia | Septicemia | Septicemia | ||||||
| Primary gastritis | ||||||||
| 2° pneumonia | Peyer patches | Olfactory neuritis | Conjunctivitis | |||||
| Mesenteric LN | Brain abscess | |||||||
a Mortality indicated for retained dose of 103 cfu in the lungs or nasal cavity; cfu, colony-forming unit. Data from references 69 and 75–77.
Table 5. Upper respiratory tract symptoms in bacterial select agents
| Symptoms | Percentage of patients with symptom (%) | |||||
|---|---|---|---|---|---|---|
| Plaguea (Pharyngeal) | Tularemia (Oropharyngeal) | Anthrax (Nasopharynx) | Anthrax (Oropharyngeal) | Anthrax (Laryngeal) | Melioidosis (Pharyngocervical) | |
| Fever | 92 | 96 | 83 | 97 | 50 | 60 |
| Tonsillitis | 75 | - | - | 63 | - | 15 |
| Pharyngitis | 92 | 81 | 33 | 72 | - | 30 |
| Nasal/sinus complaints | - | - | 83 | 3 | 0 | 10 |
| Malaise/fatigue | 92 | 54 | 33 | - | 25 | - |
| Headache | 92 | 62 | 17 | 6 | 0 | - |
| Cervical/submandibular lymphadenitis | 83 | 92 | 50 | 100 | - | 85 |
| Arthralgia/myalgia | 83 | 35 | - | - | - | 5 |
| Abdominal pain | 50 | - | 17 | 25 | - | |
| Vomiting/nausea | 50 | - | 0 | 3 | 25 | 5 |
| Cough | 42 | - | 0 | 6 | 0 | 5 |
| Dysphagia | 17 | - | 17 | - | 0 | - |
| Diarrhea | 17 | - | - | 3 | - | - |
| Hemoptysis/dyspnea | 8 | - | 17 | 39 | 75 | - |
| Anorexia | - | 46 | 17 | - | - | - |
| Depression | - | 50 | 17 | - | 0 | - |
| Concentration | - | 42 | - | - | - | - |
| Sleep disturbance | - | 46 | - | - | - | - |
a Also known as tonsillar plague. Data taken from references 107–113, 117, 118, 121, and 124–128.